Image

Malaria Vaccine R78C: Oxford and Serum Institute Join Forces

Malaria Vaccine R78C: Oxford and Serum Institute Join Forces

A Global Collaboration Against Malaria

The University of Oxford and the Serum Institute of India (SII) have inked a licensing deal to produce and manufacture R78C, a new malaria vaccine.The agreement is likely to help speed up efforts to eradicate malaria, which still kills millions of people, especially children, in sub-Saharan Africa.

 


What Is the R78C Vaccine?

R78C aims to combat Plasmodium falciparum, the most deadly malaria parasite.

R78C is the first malaria vaccine to use a multi-stage strategy to target the parasite at different stages of its life cycle. It contains two blood-stage antigens:

  • RIPR
  • CyPRA

The vaccine will target the parasite at different developmental points to:

  • Generate a stronger immune response
  • Reduce disease severity
  • Limit transmission

This is a major development in malaria vaccine strategies.


Why the Oxford-Serum Partnership is Key

SII's presence is vital for its unique manufacturing capacity. As the world's largest volume vaccine producer, it can:

Scale up production efficiently
Ensure affordability
Facilitate global roll-out

The partnership is also a continuation of previous work, such as the creation of the R21/Matrix-M malaria vaccine, underscoring a commitment to innovation and access.


R78C's Approach to Vaccines

Existing vaccines, such as R21/Matrix-M, focus on the sporozoite stage of malaria, the initial stage of infection.

R78C, however:

  • Tackles the blood stage , when the disease is severe
  • Seeks to prevent complications and death
  • May work with other vaccines to provide greater immunity

Scientists hope a multistage vaccine may help with long-term immunity and address issues like vaccine 'decline'.


A Vaccine to Reduce Malaria's Burden

Malaria is a significant disease burden, particularly in developing countries. An improved vaccine could:

  • Reduce disease burden and deaths
  • Increase survival rates of children
  • Support long-term eradication efforts

The deal also showcases India's emerging importance in the field of health through mass production of low-cost vaccines.


Next Steps in Development

R78C is in the research and clinical trial stage. The agreement will support:

  • Faster progression through clinical trials
  • Manufacturing readiness
  • Future large-scale distribution

The vaccine would undergo several stages of testing and approval before being made available to the public.

If it is successful, R78C could become part of the new generation of malaria vaccines, paving the way to disease control and eradication.


Exam-Focused Points

  • Oxford and Serum Institute enter deal to create R78C malaria vaccine.
  • Aims to stop Plasmodium falciparum , the most deadly malaria parasite.
  • Multi- stage (blood-stage antigens RIPR and CyPRA).
  • Not like R21/Matrix-M, which targets sporozoite.
  • SII allows cost-effective vaccine manufacturing.
  • R78C is in clinical trials .
  • Malaria can be prevented through vaccines, mosquito control and treatment.

Month: 

Category: 

1